• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用混合贝叶斯网络对复发性乳腺癌患者进行生存分析。

Survival analysis of recurrent breast cancer patients using mix Bayesian network.

作者信息

Shahmirzalou Parviz, Khaledi Majid Jafari, Khayamzadeh Maryam, Rasekhi Aliakbar

机构信息

Department of Biostatistics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.

Department of Statistics, Tarbiat Modares University, Tehran, Iran.

出版信息

Heliyon. 2023 Sep 21;9(10):e20360. doi: 10.1016/j.heliyon.2023.e20360. eCollection 2023 Oct.

DOI:10.1016/j.heliyon.2023.e20360
PMID:37780765
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10539960/
Abstract

INTRODUCTION

Breast cancer (BC) is the most common cancer among women. Iranians have an 11% BC recurrence rate, which lowers their survival rates. Few studies have investigated cancer recurrence survival rates. This study's major purpose is to use a mixed Bayesian network (BN) to analyze recurrent patients' survival.

MATERIAL AND METHODS

This study aimed to evaluate the pathobiological features, age, gender, final status, and survival time of the patients. Bayesian imputation was used for missing data. The performance of BN was optimized through the utilization of a blacklist and prior probability. After structural and parametric learning, posterior conditional probabilities and mean survival periods for the node arcs were predicted. The hold-out technique based on the posterior classification error was used to investigate the model's validation.

RESULTS

The study included 220 cancer recurrence patients. These patients averaged 47 years old. The BN with a blacklist and prior probability has a higher network score than other networks. The hold-out technique verified structural learning. The Directed Acyclic Graph showed a statistically significant relationship between cancer biomarkers (ER, PR, and HER2 receptors), cancer stage, and tumor grade and patient survival duration. Patient death was also significantly associated with education, ER, PR, HER2, and tumor grade. The BN reports that HER2 negative, ER positive, and PR positive patients had a higher survival rate.

CONCLUSION

Survival and death of relapsed patients depend on biomarkers. Based on the findings, patient survival can be predicted with their features.

摘要

引言

乳腺癌(BC)是女性中最常见的癌症。伊朗人的乳腺癌复发率为11%,这降低了他们的生存率。很少有研究调查癌症复发后的生存率。本研究的主要目的是使用混合贝叶斯网络(BN)来分析复发患者的生存情况。

材料与方法

本研究旨在评估患者的病理生物学特征、年龄、性别、最终状态和生存时间。对缺失数据采用贝叶斯插补法。通过使用黑名单和先验概率来优化贝叶斯网络的性能。在进行结构和参数学习后,预测节点弧的后验条件概率和平均生存期。基于后验分类误差的留出法用于研究模型的验证。

结果

该研究纳入了220例癌症复发患者。这些患者的平均年龄为47岁。带有黑名单和先验概率的贝叶斯网络比其他网络具有更高的网络得分。留出法验证了结构学习。有向无环图显示癌症生物标志物(雌激素受体、孕激素受体和人表皮生长因子受体2)、癌症分期和肿瘤分级与患者生存时间之间存在统计学上的显著关系。患者死亡也与教育程度、雌激素受体、孕激素受体、人表皮生长因子受体2和肿瘤分级显著相关。贝叶斯网络报告显示,人表皮生长因子受体2阴性、雌激素受体阳性和孕激素受体阳性的患者生存率较高。

结论

复发患者的生存和死亡取决于生物标志物。基于这些发现,可以根据患者的特征预测其生存情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1131/10539960/94b497c15fb2/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1131/10539960/2e99295cf873/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1131/10539960/3ec9314ab0f5/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1131/10539960/5b1884d8c0e3/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1131/10539960/94b497c15fb2/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1131/10539960/2e99295cf873/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1131/10539960/3ec9314ab0f5/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1131/10539960/5b1884d8c0e3/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1131/10539960/94b497c15fb2/gr4.jpg

相似文献

1
Survival analysis of recurrent breast cancer patients using mix Bayesian network.使用混合贝叶斯网络对复发性乳腺癌患者进行生存分析。
Heliyon. 2023 Sep 21;9(10):e20360. doi: 10.1016/j.heliyon.2023.e20360. eCollection 2023 Oct.
2
The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score.Luminal B(HER2 阴性)的重新分组,是一个更好的预后和复发评分的区分指标。
Cancer Med. 2023 Feb;12(3):2493-2504. doi: 10.1002/cam4.5089. Epub 2022 Jul 31.
3
Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.国家综合癌症网络中三阴性乳腺癌女性的临床病理特征、复发模式和生存情况。
Cancer. 2012 Nov 15;118(22):5463-72. doi: 10.1002/cncr.27581. Epub 2012 Apr 27.
4
Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.伴有脑转移的乳腺癌:临床病理特征、生存情况及配对生物标志物分析。
Oncologist. 2015 May;20(5):466-73. doi: 10.1634/theoncologist.2014-0107. Epub 2015 Mar 23.
5
Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.单激素受体阳性乳腺癌的预后较差:与三阴性乳腺癌的结局相似。
BMC Cancer. 2015 Mar 18;15:138. doi: 10.1186/s12885-015-1121-4.
6
Bayesian network ensemble as a multivariate strategy to predict radiation pneumonitis risk.贝叶斯网络集成作为预测放射性肺炎风险的多变量策略。
Med Phys. 2015 May;42(5):2421-30. doi: 10.1118/1.4915284.
7
Predictors of time to death after distant recurrence in breast cancer patients.乳腺癌远处复发后死亡时间的预测因素。
Breast Cancer Res Treat. 2019 Jan;173(2):465-474. doi: 10.1007/s10549-018-5002-9. Epub 2018 Oct 16.
8
Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material.关于诊断性肿瘤活检与肿瘤切除组织中雌激素、孕激素和 HER2 受体表达不一致的真实世界数据。
Breast Cancer Res Treat. 2019 Jun;175(2):451-458. doi: 10.1007/s10549-019-05141-y. Epub 2019 Feb 13.
9
Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.基于免疫组织化学亚型(ER/PR/HER2)的乳腺癌生存分析:一项回顾性队列研究。
Arch Iran Med. 2016 Oct;19(10):680-686.
10
The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.分子亚型对接受当代辅助治疗的年轻女性乳腺癌复发的影响。
Breast J. 2018 Mar;24(2):148-153. doi: 10.1111/tbj.12853. Epub 2017 Jul 14.

本文引用的文献

1
Ten-Year Survival of Breast Cancer in Iran: A National Study (Retrospective Cohort Study).伊朗乳腺癌患者的十年生存率:一项全国性研究(回顾性队列研究)。
Breast Care (Basel). 2023 Feb;18(1):12-21. doi: 10.1159/000526746. Epub 2022 Sep 14.
2
Characterizing Clinicopathologic Features of Estrogen Receptor-Positive/Progesterone Receptor-Negative Breast Cancers.描述雌激素受体阳性/孕激素受体阴性乳腺癌的临床病理特征。
Clin Breast Cancer. 2022 Oct;22(7):e788-e797. doi: 10.1016/j.clbc.2022.07.001. Epub 2022 Jul 9.
3
Update on prognostic and predictive biomarkers of breast cancer.
乳腺癌预后和预测生物标志物的最新进展。
Semin Diagn Pathol. 2022 Sep;39(5):322-332. doi: 10.1053/j.semdp.2022.06.015. Epub 2022 Jun 18.
4
Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study.ER 阳性/HER2 阴性绝经后乳腺癌患者复发后总生存相关因素:JBCRG-C06 Safari 研究的一项特别分析。
Jpn J Clin Oncol. 2022 May 31;52(6):545-553. doi: 10.1093/jjco/hyac022.
5
Breast cancer recurrence: factors impacting occurrence and survival.乳腺癌复发:影响发生及生存的因素
Ir J Med Sci. 2022 Dec;191(6):2501-2510. doi: 10.1007/s11845-022-02926-x. Epub 2022 Jan 25.
6
Machine Learning to Discern Interactive Clusters of Risk Factors for Late Recurrence of Metastatic Breast Cancer.机器学习识别转移性乳腺癌晚期复发危险因素的交互簇
Cancers (Basel). 2022 Jan 5;14(1):253. doi: 10.3390/cancers14010253.
7
Socioeconomic position and prognosis in premenopausal breast cancer: a population-based cohort study in Denmark.社会经济地位与绝经前乳腺癌预后的关系:丹麦基于人群的队列研究。
BMC Med. 2021 Sep 30;19(1):235. doi: 10.1186/s12916-021-02108-z.
8
Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review.乳腺癌——流行病学、危险因素、分类、预后标志物及当前治疗策略——最新综述
Cancers (Basel). 2021 Aug 25;13(17):4287. doi: 10.3390/cancers13174287.
9
Association of Biomarker Discrepancy and Treatment Decision, Disease Outcome in Recurrent/Metastatic Breast Cancer Patients.复发性/转移性乳腺癌患者生物标志物差异与治疗决策、疾病转归的关联
Front Oncol. 2021 Jul 1;11:638619. doi: 10.3389/fonc.2021.638619. eCollection 2021.
10
A New Method for Imputing Censored Values in Crossover Designs with Time-to-Event Outcomes Using Median Residual Life.利用中位残余寿命对有删失的生存时间交叉设计进行插补的新方法。
Biomed Res Int. 2020 Dec 10;2020:8475154. doi: 10.1155/2020/8475154. eCollection 2020.